Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock
Praxis Precision Medicines Inc. (PRAX) rallied 2% after analysts increased their price targets, following the company's submissions to the FDA for two experimental drugs, ulixacaltamide and relutrigine, both of which have Breakthrough Therapy Designation. Truist raised its price target to $700 from $500 with a 'Buy' rating, while Wedbush raised its target to $130 from $95 with an 'Underperform' rating, and Wells Fargo increased its target to $305 from $282 with an 'Equal Weight' rating. Praxis CEO Marcio Souza anticipates the company transitioning into a commercial entity and projects over $20 billion in revenue potential from its four assets.
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock
Praxis Precision Medicines (PRAX) shares rallied after analysts increased their price targets following the company's FDA submissions for two experimental drugs, ulixacaltamide and relutrigine, both of which have Breakthrough Therapy Designation. Truist raised its price target to $700, citing the completed NDA submissions as "notable," while Wells Fargo expressed surprise that priority review wasn't requested for Ulixadolid despite its breakthrough status. Wedbush also increased its price target but maintained an 'Underperform' rating, holding reservations on the ulixacaltamide filing.
Praxis Precision Medicines stock reaches 52-week high at 337.01 USD
Praxis Precision Medicines Inc. (PRAX) stock achieved a 52-week high of $337.01, now trading at $338.50, reflecting a 347.17% one-year change and a 633% six-month return. Despite a recent EPS miss, investor confidence is bolstered by strong cash reserves and a promising product pipeline, including two new drug applications and a breakthrough therapy designation. Truist Securities reiterated a Buy rating with a $500 price target, based on pricing expectations for its drug ulixa.
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results
Praxis Precision Medicine (NASDAQ: PRAX) reported a wider-than-expected Q4 loss. Despite this, several analysts raised their price targets for the stock, citing the company's clinical and regulatory advancements and potential for future revenue from pipeline assets. The company's CEO, Marcio Souza, highlighted two NDA submissions and two programs with upcoming topline results, projecting over $20 billion in revenue potential from four key assets.
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year High Following Analyst Upgrade
Praxis Precision Medicines (NASDAQ:PRAX) reached a new 52-week high after Truist Financial raised its price target to $700, with other firms also increasing their targets. The company recently filed two New Drug Applications (NDAs), for ulixacaltamide and relutrigine, a move seen as a major de-risking step. Despite a Q4 EPS miss and mixed analyst views, institutional investors have increased their holdings, contributing to the stock's momentum.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2025 Earnings Call Transcript
Praxis Precision Medicines (NASDAQ:PRAX) reported its Q4 and full-year 2025 financial results, highlighting significant clinical achievements and regulatory advancements across its portfolio, including NDA submissions for ulixacaltamide and relutrigine. The company announced pipeline updates for vormatrigine and elsunersen, with multiple readouts expected throughout 2026. Praxis ended Q4 with $926 million in cash, which, combined with a January 2026 offering, brings its pro forma cash to $1.5 billion, expected to fund operations into 2028.
PRAX: NDAs filed for two CNS drugs; strong cash position funds operations into 2028
Praxis Precision Medicines (PRAX) has filed two New Drug Applications (NDAs) for late-stage CNS assets and plans commercial launches pending FDA approval. The company currently holds over $926 million in cash and investments, which is expected to fund operations until 2028, with additional program results anticipated in 2026. This information was detailed in a recent SEC 8-K filing.
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Praxis Precision Medicines has submitted two new drug applications (NDAs) to the FDA for ulixacaltamide in essential tremor and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), with pre-launch activities underway. The company reported $926 million in cash and investments as of December 31, 2025, with an additional $621 million from a January 2026 public offering, funding operations into 2028. This update highlights significant progress in their Cerebrum™ and Solidus™ platforms, with multiple programs advancing through clinical trials and expected topline results in the first half of 2026.
Praxis Precision Medicines, Inc. (Praxis) recently disclosed the company's operational progress and financial report for the fourth quarter and full year of 2025.
Praxis Precision Medicines, Inc. recently released its operational progress and financial report for the fourth quarter and full year of 2025. This announcement provides key business milestones and financial data for investors. The article also includes a disclaimer that its content reflects the author's opinion and is not intended as investment advice.
Praxis lines up 4 brain drugs with $20B revenue potential
Praxis Precision Medicines reported its Q4 and full-year 2025 financial results, alongside significant corporate updates. The company submitted two New Drug Applications (NDAs) for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs) and expects topline results for two other programs, vormatrigine and elsunersen, in the first half of 2026. Praxis anticipates these four assets could generate over $20 billion in revenue, with current funding projected to last into 2028.
Earnings Breakdown: Praxis Precision Medicine Q4
Praxis Precision Medicine (NASDAQ: PRAX) reported its Q4 earnings, missing estimated earnings per share (EPS) by -13.64% with an EPS of $-3.5 against an estimate of $-3.08. Revenue also declined by $7.46 million compared to the same period last year. In the previous quarter, the company had beaten EPS expectations, leading to a 4.68% increase in share price the following day.
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide
Praxis Precision Medicines Inc. (PRAX) has received increased price targets and reiterated Buy/Overweight ratings from Guggenheim and Piper Sandler due to the significant market opportunity and success of its essential tremor treatment, ulixacaltamide. Analysts project multi-billion dollar peak sales for the drug and substantial revenue for the company, also noting progress in relutrigine and epileptic encephalopathies. The essential tremor market is valued at over $15 billion, positioning Praxis for considerable growth in neurology.
Wells Fargo Cautious on Praxis Precision (PRAX) After Recent Revenue Estimates
Wells Fargo has initiated coverage on Praxis Precision Medicines (PRAX) with an "Equal Weight" rating and a $282 price target, expressing caution despite the company's ambitious revenue projections. While Praxis anticipates up to $20 billion in peak revenue from four drugs over the next 24 months, Wells Fargo assigns only a 50% probability of success for ulixacaltamide, a key investigational treatment for essential tremor. The bank's assessment suggests a more conservative outlook compared to the company's bullish self-assessment.
Praxis Precision earnings on deck as dual NDA filings loom
Praxis Precision Medicines (PRAX) is set to report Q4 and full-year 2025 earnings before anticipated New Drug Application (NDA) filings for two key therapies: ulixacaltamide for essential tremor and relutrigine for rare epilepsies. Analysts expect a loss of $3.09 per share on $398,000 revenue. The company also recently raised $621 million, extending its cash runway into 2028, and possesses a Strong Buy rating with significant upside potential.
Understanding Momentum Shifts in (PRAX)
Praxis Precision Medicines Inc. (NASDAQ: PRAX) is currently experiencing a mid-channel oscillation pattern with strong sentiment supporting an overweight bias across all horizons. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 76.0:1 risk-reward short setup, targeting a 22.0% downside against a minimal 0.3% risk.
Praxis Precision Medicines Nears Commercial Launch with Key FDA Submissions
Praxis Precision Medicines is transitioning to a commercial-stage company, preparing for the imminent submission of two New Drug Applications (NDAs) to the FDA for ulixacaltamide and relutrigine, both granted Breakthrough Therapy designation. The company has a strong financial position with $1.5 billion in cash, funding operations through 2028, and anticipates releasing Q4/full-year 2025 financial results and providing strategic updates in upcoming investor events. Additionally, pivotal data readouts for vormatrigine and elsunersen are expected later this year, with ulixacaltamide targeting a significant market in essential tremor.
Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)
Guggenheim analyst Yatin Suneja raised the price target for Praxis Precision Medicines (PRAX) from $760 to $800, maintaining a Buy rating due to the estimated $15 billion market potential of ulixacaltamide. H.C. Wainwright analyst Douglas Tsao also increased his price target to $1,245, citing ulixacaltamide as "transformative" and expecting relutrigine to drive significant value with projected peak sales of $6.8 billion. Praxis Precision Medicines focuses on developing therapies for central nervous system disorders using proprietary platforms.
Praxis Precision Medicines (PRAX) Valuation After Analyst Upgrades And Key Breakthrough Therapy NDA Plans
Praxis Precision Medicines (PRAX) is gaining investor attention due to analyst upgrades and upcoming NDA submissions for its lead drug candidates, ulixacaltamide and relutrigine, both holding Breakthrough Therapy Designation. While the company has seen significant share price growth, trading at a P/B ratio high above industry averages suggests considerable optimism is already priced in. Investors should consider whether future earnings and cash flows will meet these high expectations.
Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800
Guggenheim raised its target price on Praxis Precision Medicines (PRAX) to $800 from $760, reiterating a Buy recommendation. This adjustment follows a reassessment of Ulixacaltamide's potential impact on the essential tremors market, with anticipated peak sales of $5 billion to $10 billion. The drug recently received "Breakthrough Therapy Designation" from the FDA, and Praxis plans to submit a New Drug Application by February 2026.
Praxis Precision Medicines (PRAX) Valuation After Analyst Upgrades And Key Breakthrough Therapy NDA Plans
Praxis Precision Medicines (PRAX) is gaining attention due to analyst confidence in its lead drug candidates and upcoming NDA submissions for ulixacaltamide and relutrigine, both holding Breakthrough Therapy Designation. The stock has seen significant momentum, with a strong 1-year return, but its P/B ratio indicates high market optimism. While a model suggests a fair value of $449.13, highlighting potential undervaluation, this hinges on successful pivotal epilepsy trials and physician adoption of vormatrigine.
Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800
Guggenheim has increased its price target on Praxis Precision Medicines (PRAX) to $800 from $760, reiterating a Buy recommendation. This adjustment follows a reassessment of the potential peak sales of Ulixacaltamide, an essential tremor drug, which the firm now projects could reach $5 billion to $10 billion. The drug recently received "Breakthrough Therapy Designation" from the FDA, and Praxis plans to submit a New Drug Application by early 2026.
Why Praxis Precision Medicines (PRAX) Is Up 6.6% After Dual NDA Timeline and Investor Push - And What's Next
Praxis Precision Medicines (PRAX) is up 6.6% following its presentation at a biotech summit and upcoming Q4/full-year 2025 results announcement. The company is preparing for dual New Drug Application (NDA) submissions by mid-February for ulixacaltamide and relutrigine, both holding FDA Breakthrough Therapy Designations. This surge is driven by aligning investor outreach with imminent regulatory milestones, indicating a potential shift towards commercial readiness despite still being a loss-making company.
Arizona State Retirement System Purchases Shares of 5,417 Praxis Precision Medicines, Inc. $PRAX
The Arizona State Retirement System recently acquired 5,417 shares of Praxis Precision Medicines (NASDAQ:PRAX) valued at approximately $287,000, as part of a trend where institutional investors now own 67.84% of the stock. This comes amidst significant insider selling by two executives in November and a consensus analyst rating of "Moderate Buy" with a target price considerably higher than its current trading value near its 52-week high. Praxis Precision Medicines is a biopharmaceutical company focused on developing therapies for neurological and psychiatric conditions.
PRAX: Two NDAs set for mid-February aim to address major CNS markets with strong launch plans
Praxis Precision Medicines (PRAX) is preparing to file two New Drug Applications (NDAs) in mid-February to address significant unmet needs in essential tremor and epilepsy. The company plans a robust commercial strategy for its new therapies, targeting a price range of $40,000–$60,000, and has sufficient cash reserves to fund launches into 2028. This information comes from an AI-generated summary of their Guggenheim Securities Emerging Outlook Biotech Summit 2026 audio transcript.
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High - Here's Why
Praxis Precision Medicines (NASDAQ:PRAX) recently reached a new 52-week high of $328.27, trading at $324.75 with strong momentum, as indicated by its moving averages and a market cap of $8.05 billion. This surge follows significant analyst upgrades, with price targets as high as $1,245, leading to a "Moderate Buy" consensus. Despite some insider selling in November, institutional ownership remains high, with major funds increasing their stakes.
Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity
Guggenheim has increased its price target for Praxis Precision Medicines Inc. (PRAX) to $800.00 from $760.00, maintaining a Buy rating, citing the substantial market opportunity for ulixacaltamide in essential tremor, which could reach $5-10 billion in peak sales. The stock has seen a 595% increase over the past six months, with FDA approval for ulixacaltamide expected this year following an upcoming NDA submission. Other analysts like H.C. Wainwright and Piper Sandler have also raised their price targets significantly.
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines announced it will report its Q4 and Full Year 2025 financial results on Thursday, February 19, 2026, before market open, followed by a conference call and webcast. The company will also participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11 and the TD Cowen 46th Annual Health Care Conference on March 2, with corporate presentations at both events. Praxis, a precision neuroscience biopharmaceutical company, will provide a corporate update alongside its financial report.
Praxis Precision Medicines stock hits 52-week high at 327.0 USD
Praxis Precision Medicines Inc. stock reached a 52-week high of $327.0 USD, marking a 282.69% increase over the year and a 595.62% surge in the past six months, with a market capitalization of $9.02 billion. This growth is supported by positive developments including plans to submit two New Drug Applications (NDAs) to the FDA by mid-February 2026 for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation. Analyst price targets remain bullish, with H.C. Wainwright and Piper Sandler significantly raising their targets due to anticipated drug approvals and high sales estimates.
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines announced it will release its fourth quarter and full year 2025 financial results and provide a corporate update on February 19, 2026. The company will host a conference call and live webcast for these results. Additionally, Praxis management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 and the TD Cowen 46th Annual Health Care Conference in February and March 2026, respectively.
Praxis Precision Medicines to Report Fourth Quarter and
Praxis Precision Medicines will report its fourth quarter and full year 2025 financial results and provide a corporate update on Thursday, February 19, 2026, before market open. The company will host a conference call and live webcast for these results. Additionally, Praxis management will participate in two upcoming investor conferences: the Guggenheim Emerging Outlook: Biotech Summit 2026 and the TD Cowen 46th Annual Health Care Conference.
Praxis Precision Medicines stock hits 52-week high at 327.0 USD By Investing.com
Praxis Precision Medicines Inc. (PRAX) stock has reached a new 52-week high of $327.00, representing a 282.69% increase over the past year and a 595.62% surge in the last six months, with its market capitalization now at $9.02 billion. Despite its high volatility (beta of 2.9) and trading above its "Fair Value" according to InvestingPro, analysts maintain a bullish outlook with a consensus "Buy" recommendation and a high price target of $1,245. The company plans to submit two New Drug Applications (NDAs) to the FDA by mid-February 2026 for essential tremor and SCN2A/8A developmental and epileptic encephalopathies.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule
Praxis Precision Medicines, Inc. announced inducement grants in accordance with Nasdaq Listing Rule. The announcement was made through Reuters and indicates a corporate action by Praxis Precision Medicines, Inc.
Is Praxis Precision Medicines (PRAX) Now Pricing In Recent Pipeline Progress And Volatile Share Gains
Praxis Precision Medicines (PRAX) has seen volatile share gains recently, with a 243.8% return over the past year. While a Discounted Cash Flow (DCF) analysis suggests the stock could be significantly undervalued by 90.5%, its Price to Book (P/B) ratio of 24.50x is considerably higher than the industry average, indicating it might be overvalued by this metric. Investors are encouraged to consider different valuation narratives and the underlying financial forecasts when assessing the company's true worth.
Is Praxis Precision Medicines (PRAX) Now Pricing In Recent Pipeline Progress And Volatile Share Gains
Praxis Precision Medicines (PRAX) has seen volatile share gains recently, including a 243.8% return over one year, driven by pipeline progress and regulatory milestones. While a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 90.5%, its Price to Book (P/B) ratio of 24.50x indicates it is overvalued compared to industry averages. Investors are encouraged to use "Narratives" on Simply Wall St to integrate their views with financial forecasts for a more tailored valuation.
Biotech Praxis hands 2,964 stock units to eight new hires
Praxis Precision Medicines (PRAX) announced an inducement grant of 2,964 restricted stock units to eight new non-executive employees on February 2, 2026. These awards, made under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments, contingent on continued employment. This action is a routine strategy to attract new talent to the company.
Why Praxis Precision Medicines (PRAX) Is Up 5.1% After Dual NDA Plans And Data Platform Expansion
Praxis Precision Medicines' stock rose by 5.1% following announcements of plans to submit two New Drug Applications (NDAs) to the FDA for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation. The company also expanded its use of SEQSTER’s data platform to enhance trial efficiency and improve the commercial positioning of its central nervous system drug candidates. While these developments bring regulatory catalysts closer and aim to de-risk execution, Praxis remains unprofitable, reliant on external capital, and exposed to significant clinical and FDA outcome risks.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 2,964 shares to eight new non-executive employees on February 2, 2026. These grants were made under the company's 2024 Inducement Plan as material inducements for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, contingent upon the employees' continued employment.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. has announced inducement grants of restricted stock units covering 2,964 shares to eight new non-executive employees. These grants were made on February 2, 2026, under the company's 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are designed to incentivize new employees and will vest in four equal annual installments, contingent on continued employment.
Why Praxis Precision Medicines (PRAX) Is Up 5.1% After Dual NDA Plans And Data Platform Expansion
Praxis Precision Medicines (PRAX) saw a 5.1% stock increase after announcing plans to submit two New Drug Applications (NDAs) for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation. The company also expanded its use of SEQSTER’s data platform to improve trial efficiency and the positioning of its neurology drug candidates. This move is expected to influence Praxis's investment narrative by bringing regulatory catalysts and commercial discussions forward, while the expanded data partnership aims to de-risk execution.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 2,964 shares to eight new non-executive employees on February 2, 2026. These grants were made under the 2024 Inducement Plan, which is used to attract new talent and complies with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, contingent on the employees' continued employment.
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX)
The article highlights bullish sentiments from analysts for two healthcare stocks: Regeneron (REGN) and Praxis Precision Medicines (PRAX). BMO Capital maintained a Buy rating for Regeneron with an $850 price target, while LifeSci Capital maintained a Buy rating for Praxis Precision Medicines with a $534 price target. The analyst consensus for Regeneron is a Moderate Buy with a 13.1% upside, and for Praxis Precision Medicines, it's a Strong Buy with an 87.2% upside.
Wells Fargo Initiates Coverage on PRAX with Equal-Weight Rating
Wells Fargo has initiated coverage on Praxis Precision Medicine (PRAX) with an Equal-Weight rating and a price target of $282.00 USD. This follows recent rating changes from other analysts, which range from "Underperform" to "Buy," indicating varied market perspectives on the biotech company. Despite a wide range of analyst price targets, the average target suggests an 86.25% upside, though GuruFocus' GF Value estimates a 7.49% downside.
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders
SEQSTER and Praxis Precision Medicines have expanded their partnership to accelerate clinical trials, data collection, and real-world evidence generation for CNS disorders. SEQSTER's platform provides automated access to patient-consented electronic health records, which aids in patient screening, enrollment, and ongoing data collection for Praxis's clinical development programs, including the ENERGY program for epilepsy. This collaboration aims to deliver life-altering treatments to patients faster and more effectively by leveraging real-world data.
Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target
Wells Fargo has initiated coverage on Praxis Precision Medicines (PRAX) with an "Equal Weight" rating and set a price target of $282. The announcement was made by MT Newswires, highlighting new analyst interest in the biopharmaceutical company. Praxis Precision Medicines focuses on developing therapies for central nervous system disorders.
Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at Wells Fargo & Company
Wells Fargo & Company has initiated coverage on Praxis Precision Medicines (NASDAQ:PRAX) with an "equal weight" rating and a price target of $282.00, suggesting a potential downside of 10.19% from its current price. This new coverage adds to a mixed but generally bullish analyst outlook, with other firms assigning significantly higher price targets. The company, which has a market cap of $7.91 billion and a negative P/E ratio, recently saw insider share sales in November, while institutional investors hold approximately 67.8% of its stock.
A Look At Praxis Precision Medicines (PRAX) Valuation After Breakthrough NDA Plans And Rising Investor Interest
Praxis Precision Medicines (PRAX) is gaining investor attention due to its plans to file two New Drug Applications for ulixacaltamide and relutrigine, both designated as Breakthrough Therapies. Despite recent share price volatility, the company is seen as undervalued, with a fair value pegged at $449.13 compared to its current $314, driven by its late-stage epilepsy programs. However, this optimistic outlook depends on successful trial results and market penetration for its treatments.
A Look At Praxis Precision Medicines (PRAX) Valuation After Breakthrough NDA Plans And Rising Investor Interest
Praxis Precision Medicines (PRAX) is gaining investor attention due to its plans to file two New Drug Applications for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation. The company's shares have shown significant returns, and analysts project a fair value of $449.13, suggesting it may still be undervalued despite recent growth. This valuation hinges on successful pivotal epilepsy trials and the market penetration of vormatrigine.
3,846 Shares in Praxis Precision Medicines, Inc. $PRAX Acquired by Coastal Bridge Advisors LLC
Coastal Bridge Advisors LLC recently initiated a position in Praxis Precision Medicines (NASDAQ:PRAX) by purchasing 3,846 shares valued at approximately $204,000. This comes amidst other institutional investors significantly increasing their stakes, bringing total institutional ownership to 67.84%. However, the article also notes substantial insider selling, with two key insiders collectively selling shares worth nearly $7.5 million, significantly reducing their holdings.
Y Intercept Hong Kong Ltd Makes New $1.71 Million Investment in Praxis Precision Medicines, Inc. $PRAX
Y Intercept Hong Kong Ltd has made a new investment of $1.71 million in Praxis Precision Medicines, acquiring 32,186 shares. Concurrently, high-value insider sales were reported by General Counsel Alex Nemiroff and Lauren Mastrocola, significantly reducing their holdings. Despite these sales, analyst sentiment remains positive with a "Moderate Buy" consensus and an average target price of $486.67, as the stock trades near its 12-month high with a market cap of $7.92 billion.
H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245
H.C. Wainwright significantly increased its price target for Praxis Precision Medicines Inc. (PRAX) to $1,245 from $340, while maintaining a Buy rating. This substantial hike is based on higher peak sales estimates for its key drug candidates, ulixacaltamide and relutrigine, with the latter projected to reach $6.8 billion in peak sales. The firm highlighted upcoming clinical trial readouts, such as the EMERALD study for relutrigine, as major catalysts.
